Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTCs and arthritis

This article was originally published in The Tan Sheet

Executive Summary

Recent NSAID publicity has affected the way 82% of orthopedic surgeons recommend pain relievers, according to the results of a telephone survey by Florida Hospital and the Joint Replacement Center released Aug. 10. The survey, which polled 259 specialists between June 16 and July 7, reports that 70% of orthopedic surgeons prescribe OTC medication for minor arthritis pain rather than Rx drugs. Of the group, 58% prefer Aleve, 35% recommend Advil and 7% suggest Tylenol as the first line of treatment against arthritis pain. Aleve ranked No. 1 for its "easy dosing" with "fewer pills" and long-lasting relief. The survey measured how surgeons are reacting to new NSAID data and reports that 90% of orthopedic surgeons have decreased prescribing COX-2 inhibitors in favor of OTCs...

You may also be interested in...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?

“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts